Sympathetic and renin-angiotensin-aldosterone system activation in heart failure with preserved, mid-range and reduced ejection fraction
- PMID: 31443984
- DOI: 10.1016/j.ijcard.2019.08.040
Sympathetic and renin-angiotensin-aldosterone system activation in heart failure with preserved, mid-range and reduced ejection fraction
Abstract
Background: Evidence of sympathetic and renin-angiotensin-aldosterone system activation provided a rationale for neurohormonal antagonism in heart failure with reduced ejection fraction (HFrEF), while no data are available in patients with milder degree of systolic dysfunction. We aimed to investigate neurohormonal function in HF with preserved and mid-range EF (HFpEF/HFmrEF).
Methods: Three cohorts (n = 189/each) of stable HFpEF, HFmrEF and HFrEF patients were selected (median age 70, 67 and 67 years; male 56%, 73% and 74%, respectively). Patients received a baseline clinical assessment including plasma renin activity (PRA), aldosterone, catecholamines, and N-terminal fraction of pro-B-type natriuretic peptide (NT-proBNP) assays, and were followed-up for all-cause death.
Results: Neuroendocrine profile was similar between HFpEF and HFmrEF, while all neurohormones except epinephrine were higher in HFrEF than in HFmrEF (NT-proBNP 2332 ng/L, IQR 995-5666 vs 575 ng/L, 205-1714; PRA 1.7 ng/mL/h, 0.4-5.6 vs 0.6 ng/mL/h, 0.2-2.6; aldosterone 153 ng/L, 85-246 vs 113 ng/L, 72-177; norepinephrine 517 ng/L, 343-844 vs 430 ng/L, 259-624; all p < 0.001, epinephrine 31 ng/L, 10-63 vs 25 ng/L, 10-44; p = 0.319). These findings were unrelated to treatment heterogeneity. Ten percent of HFpEF patients had elevated PRA, aldosterone and norepinephrine vs. 8% in HFmrEF and 21% in HFrEF. During a 5-year follow-up, survival decreased with the number of neurohormones elevated (HFpEF: log-rank 7.8, p = 0.048; HFmrEF: log-rank 11.8, p = 0.008; HFrEF: log-rank 8.1, p = 0.044).
Conclusions: Neurohormonal activation is present only in a subset of patients with HFpEF and HFmrEF, and may hold clinical significance. Neurohormonal antagonism may be useful in selected HFpEF/HFmrEF population.
Keywords: Biomarkers; Ejection fraction; Heart failure; Neurohormones.
Copyright © 2019 Elsevier B.V. All rights reserved.
Similar articles
-
Heart failure with mid-range or mildly reduced ejection fraction.Nat Rev Cardiol. 2022 Feb;19(2):100-116. doi: 10.1038/s41569-021-00605-5. Epub 2021 Sep 6. Nat Rev Cardiol. 2022. PMID: 34489589 Free PMC article. Review.
-
Associations With and Prognostic and Discriminatory Role of N-Terminal Pro-B-Type Natriuretic Peptide in Heart Failure With Preserved Versus Mid-range Versus Reduced Ejection Fraction.J Card Fail. 2018 Jun;24(6):365-374. doi: 10.1016/j.cardfail.2018.03.010. Epub 2018 Mar 27. J Card Fail. 2018. PMID: 29597053
-
A comprehensive population-based characterization of heart failure with mid-range ejection fraction.Eur J Heart Fail. 2017 Dec;19(12):1624-1634. doi: 10.1002/ejhf.945. Epub 2017 Sep 25. Eur J Heart Fail. 2017. PMID: 28948683
-
Bio-profiling and bio-prognostication of chronic heart failure with mid-range ejection fraction.Int J Cardiol. 2018 Apr 15;257:188-192. doi: 10.1016/j.ijcard.2018.01.119. Epub 2018 Jan 31. Int J Cardiol. 2018. PMID: 29415801
-
Renin-Angiotensin System Inhibition, Worsening Renal Function, and Outcome in Heart Failure Patients With Reduced and Preserved Ejection Fraction: A Meta-Analysis of Published Study Data.Circ Heart Fail. 2017 Feb;10(2):e003588. doi: 10.1161/CIRCHEARTFAILURE.116.003588. Circ Heart Fail. 2017. PMID: 28209765 Review.
Cited by
-
Modeling the physiological roles of the heart and kidney in heart failure with preserved ejection fraction during baroreflex activation therapy.Am J Physiol Heart Circ Physiol. 2022 Sep 1;323(3):H597-H607. doi: 10.1152/ajpheart.00329.2022. Epub 2022 Aug 19. Am J Physiol Heart Circ Physiol. 2022. PMID: 35984764 Free PMC article.
-
Current and emerging drug targets in heart failure treatment.Heart Fail Rev. 2022 Jul;27(4):1119-1136. doi: 10.1007/s10741-021-10137-2. Epub 2021 Jul 17. Heart Fail Rev. 2022. PMID: 34273070 Free PMC article. Review.
-
Heart failure with mid-range or mildly reduced ejection fraction.Nat Rev Cardiol. 2022 Feb;19(2):100-116. doi: 10.1038/s41569-021-00605-5. Epub 2021 Sep 6. Nat Rev Cardiol. 2022. PMID: 34489589 Free PMC article. Review.
-
Heart failure with mildly reduced ejection fraction: from diagnosis to treatment. Gaps and dilemmas in current clinical practice.Heart Fail Rev. 2023 Jul;28(4):767-780. doi: 10.1007/s10741-022-10267-1. Epub 2022 Jul 25. Heart Fail Rev. 2023. PMID: 35877025 Review.
-
Left ventricular dysfunction in heart failure with preserved ejection fraction-molecular mechanisms and impact on right ventricular function.Cardiovasc Diagn Ther. 2020 Oct;10(5):1541-1560. doi: 10.21037/cdt-20-477. Cardiovasc Diagn Ther. 2020. PMID: 33224773 Free PMC article. Review.
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous